<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178447</url>
  </required_header>
  <id_info>
    <org_study_id>ZP1848-18131</org_study_id>
    <secondary_id>2019-001466-15</secondary_id>
    <nct_id>NCT04178447</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function</brief_title>
  <official_title>An Open-label, Multi-center Trial to Evaluate the Pharmacokinetic Profile of Glepaglutide After a Single Subcutaneous Injection in Subjects With Varying Degrees of Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is two stage design, open-label, multi-center, non-randomized trial evaluating the PK of&#xD;
      a single, subcutaneous dose of 10 mg glepaglutide in subjects with varying degrees of renal&#xD;
      function. The renal function will be calculated by the estimated glomerular filtration rate&#xD;
      (eGFR) according to the Modification of Diet in Renal Disease (MDRD) equation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Actual">July 14, 2020</completion_date>
  <primary_completion_date type="Actual">July 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>If only Part A will be conducted total subjects of 16 will be enrolled if Part B also will be conducted up to 48 subjects will be enrolled.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Variables</measure>
    <time_frame>11 days</time_frame>
    <description>AUC0-168 area under the concentration-time curve (AUC) from time 0 to 168 hours&#xD;
Cmax maximum observed plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Variables</measure>
    <time_frame>11 days</time_frame>
    <description>Number of subject with AE/SAE as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1: ESRD subjects not on dialysis or severe RI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with eGFR &lt;15 mL/min/1.73 m2) or (eGFR 15 to &lt;30 mL/min/1.73 m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with eGFR ≥90 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: moderate RI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with eGFR 30 to &lt;60 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: mild RI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with eGFR 60 to &lt;90 mL/min/1.73 m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glepaglutide</intervention_name>
    <description>Single dose of Glepaglutide 10 mg</description>
    <arm_group_label>Group 1: ESRD subjects not on dialysis or severe RI</arm_group_label>
    <arm_group_label>Group 2: normal renal function</arm_group_label>
    <arm_group_label>Group 3: moderate RI</arm_group_label>
    <arm_group_label>Group 4: mild RI</arm_group_label>
    <other_name>ZP1848</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects&#xD;
&#xD;
               1. Able to understand and willing to sign the informed consent&#xD;
&#xD;
               2. eGFR values as defined in in the arms&#xD;
&#xD;
               3. Willing and able to comply with the study requirements&#xD;
&#xD;
               4. Male and female subjects age 18 to 70 years (both inclusive) at the time of&#xD;
                  informed consent&#xD;
&#xD;
               5. BMI 20.0 - 30.0 kg/m2 both inclusive&#xD;
&#xD;
               6. Must be willing to comply with the contraception, sperm-donation requirements,&#xD;
                  and study restrictions.&#xD;
&#xD;
                  Renally Impaired Subjects (in Addition)&#xD;
&#xD;
               7. Subject has a stable disease, including disease(s) associated with renal&#xD;
                  impairment, under medical control (ie, no changes in medication within 30 days&#xD;
                  prior to study drug administration). Stable renal impairment, defined as no&#xD;
                  clinically significant change in disease status within 3 months before screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Subjects&#xD;
&#xD;
          1. Suspicion of hypersensitivity, intolerance, or allergy to glepaglutide&#xD;
&#xD;
          2. History of alcohol or drug abuse&#xD;
&#xD;
          3. Clinically relevant abnormal medical history, abnormal findings on physical&#xD;
             examination, vital signs, clinically significant abnormalities on 12-lead ECG, or&#xD;
             laboratory tests at Screening that the Investigator judges as likely to interfere with&#xD;
             the objectives of the study or the safety of the subject except for conditions&#xD;
             associated with renal impairment in subjects with renal impairment&#xD;
&#xD;
          4. Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated&#xD;
             measurements for systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥&#xD;
             110 mmHg); current or documented history of repeated clinically significant&#xD;
             hypotension or severe episodes of orthostatic hypotension (systolic blood pressure &lt;&#xD;
             90 mmHg and/or diastolic blood pressure &lt; 50 mmHg)&#xD;
&#xD;
          5. Acute illness within 14 days prior to dosing unless mild in severity and approved by&#xD;
             the Investigator and Sponsor's medical representative&#xD;
&#xD;
          6. Presence of active infection requiring antibiotics. Ingestion of alcohol within 72&#xD;
             hours prior to study drug administration and during PK sampling period including&#xD;
             Follow-Up&#xD;
&#xD;
          7. Participation in another investigational drug study within 30 days prior to study drug&#xD;
             administration or exposure to more than three new investigational agents within 12&#xD;
             months prior to study drug administration&#xD;
&#xD;
          8. Previous exposure to GLP-1, GLP-2, human growth hormone, somatostatin, or analogues&#xD;
             thereof within 3 months prior to Screening. Use of dipeptidyl peptidase-4 inhibitors&#xD;
             within 3 months prior to Screening&#xD;
&#xD;
          9. Previous exposure to glepaglutide&#xD;
&#xD;
         10. Donation or loss of more than 450 mL blood during the 3 months before the start of&#xD;
             Screening&#xD;
&#xD;
         11. Female subjects who are breastfeeding, pregnant, or planning to become pregnant during&#xD;
             the study&#xD;
&#xD;
         12. Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody&#xD;
             (anti-HCV) or human immunodeficiency virus antibodies (anti-HIV)-1/2, unless the&#xD;
             absence of an active hepatitis B/C infection is confirmed by a polymerase chain&#xD;
             reaction (PCR) test, at Screening&#xD;
&#xD;
         13. Positive urine screen of drugs of abuse (if not due to concomitant medication) or&#xD;
             alcohol breath test at Screening and/or Day -1&#xD;
&#xD;
         14. Legal incapacity or limited legal capacity&#xD;
&#xD;
             Renally Impaired Subjects (in Addition)&#xD;
&#xD;
         15. Acute renal failure (as judged by the Investigator)&#xD;
&#xD;
         16. Renal impairment requiring dialysis&#xD;
&#xD;
         17. History of kidney transplant regardless of functionality&#xD;
&#xD;
         18. Serum albumin concentration &lt;25 g/L&#xD;
&#xD;
         19. Haemoglobin concentration &lt;100 g/L&#xD;
&#xD;
         20. Medications known to affect the elimination of serum creatinine (e.g., trimethoprim or&#xD;
             cimetidine) and competitors of renal tubular secretion (e.g., probenecid) within 60&#xD;
             days prior to study drug administration&#xD;
&#xD;
             Subjects With Normal Renal Function (in Addition)&#xD;
&#xD;
         21. Significant medical history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, haematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fázis I-es Klinikai Farmakológiai</name>
      <address>
        <city>Budapest</city>
        <zip>1077</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Imre Egyetemi Oktatókórház</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Centrum Medyczne - Prywatny Szpital</name>
      <address>
        <city>Kraków</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

